These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 9297563)
1. Various graft vs. host diseases (GvHD) in rodents can be prevented and treated by malononitrilamides (MNAs). Schorlemmer HU; Kurrle R; Bartlett RR Inflamm Res; 1997 Aug; 46 Suppl 2():S165-6. PubMed ID: 9297563 [No Abstract] [Full Text] [Related]
2. The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodents. Schorlemmer HU; Kurrle R; Bartlett RR Drugs Exp Clin Res; 1997; 23(5-6):167-73. PubMed ID: 9515226 [TBL] [Abstract][Full Text] [Related]
3. Analogues of leflunomide's primary metabolite, the malononitrilamides, prevent the development of graft-versus-host disease. Schorlemmer HU; Bartlett RR; Kurrle R Transplant Proc; 1997; 29(1-2):1298-301. PubMed ID: 9123315 [No Abstract] [Full Text] [Related]
4. Malononitrilamides inhibit the development of various murine graft-vs-host diseases. Schorlemmer HU; Kurrle R; Bartlett RR Transplant Proc; 1996 Dec; 28(6):3043-7. PubMed ID: 8962181 [No Abstract] [Full Text] [Related]
5. Regulation of alloreactivity in the popliteal lymph node assay by the new immunosuppressants: malononitrilamides. Schorlemmer HU; Ruuth E; Kurrle R Transpl Int; 1998; 11 Suppl 1():S448-51. PubMed ID: 9665036 [TBL] [Abstract][Full Text] [Related]
6. Malononitrilamides prevent the development of murine systemic lupus erythematosus-like diseases in BDF1 hybrid mice and MRL/lpr autoimmune mice. Schorlemmer HU; Brendel S; Bartlett RR Transplant Proc; 1996 Dec; 28(6):3040-2. PubMed ID: 8962180 [No Abstract] [Full Text] [Related]
7. The alloreactivity in the popliteal lymph node (PLN) assay is regulated by malononitrilamides (MNAs). Schorlemmer HU; Ruuth E; Kurrle R Int J Tissue React; 1997; 19(3-4):157-61. PubMed ID: 9506317 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of alloreactivity in the popliteal lymph node assay by malononitrilamides. Schorlemmer HU; Bartlett RR; Kurrle R Transplant Proc; 1998 Jun; 30(4):968-70. PubMed ID: 9636391 [No Abstract] [Full Text] [Related]
9. Prevention of the development of murine systemic lupus erythematosus (SLE)-like diseases by the malononitrilamides MNA 279 and MNA 715. Schorlemmer HU; Bartlett RR Inflamm Res; 1997 Aug; 46 Suppl 2():S167-8. PubMed ID: 9297564 [No Abstract] [Full Text] [Related]
10. Acute skin graft rejection can be prevented and treated in rat models by malononitrilamides. Schorlemmer HU; Schwab W; Ruuth E; Kurrle R Transplant Proc; 1996 Dec; 28(6):3048-50. PubMed ID: 8962182 [No Abstract] [Full Text] [Related]
11. Control of mouse-to-rat skin xenograft rejection by malononitrilamides. Schorlemmer HU; Kurrle R Transplant Proc; 1996 Dec; 28(6):3037-9. PubMed ID: 8962179 [No Abstract] [Full Text] [Related]
12. Synergism of the malononitrilamides 279 and 715 with cyclosporine A in the induction of long-term cardiac allograft survival. Lindner JK; Zantl N Transpl Int; 1998; 11 Suppl 1():S303-9. PubMed ID: 9665002 [TBL] [Abstract][Full Text] [Related]
13. Modulation of immunoglobulin dysregulation in graft versus host-and systemic lupus erythematosus-like diseases by malononitrilamides. Schorlemmer HU; Bartlett RR Transplant Proc; 1998 Dec; 30(8):4153-5. PubMed ID: 9865331 [No Abstract] [Full Text] [Related]